Skip to main content

Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.

Publication ,  Journal Article
Suncion, VY; Ghersin, E; Fishman, JE; Zambrano, JP; Karantalis, V; Mandel, N; Nelson, KH; Gerstenblith, G; DiFede Velazquez, DL; Breton, E ...
Published in: Circ Res
April 11, 2014

RATIONALE: Transendocardial stem cell injection (TESI) with mesenchymal stem cells improves remodeling in chronic ischemic cardiomyopathy, but the effect of the injection site remains unknown. OBJECTIVE: To address whether TESI exerts its effects at the site of injection only or also in remote areas, we hypothesized that segmental myocardial scar and segmental ejection fraction improve to a greater extent in injected than in noninjected segments. METHODS AND RESULTS: Biplane ventriculographic and endocardial tracings were recorded. TESI was guided to 10 sites in infarct-border zones. Sites were mapped according to the 17-myocardial segment model. As a result, 510 segments were analyzed in 30 patients before and 13 months after TESI. Segmental early enhancement defect (a measure of scar size) was reduced by TESI in both injected (-43.7 ± 4.4%; n=95; P<0.01) and noninjected segments (-25.1 ± 7.8%; n=148; P<0.001; between-group comparison P<0.05). Conversely, segmental ejection fraction (a measure of contractile performance) improved in injected scar segments (19.9 ± 3.3-26.3 ± 3.5%; P=0.003) but not in noninjected scar segments (21.3 ± 2.6-23.5 ± 3.2%; P=0.20; between-group comparison P<0.05). Furthermore, segmental ejection fraction in injected scar segments improved to a greater degree in patients with baseline segmental ejection fraction <20% (12.1 ± 1.2-19.9 ± 2.7%; n=18; P=0.003), versus <20% (31.7 ± 3.4-35.5 ± 3.3%; n=12; P=0.33, between-group comparison P<0.0001). CONCLUSIONS: These findings illustrate a dichotomy in regional responses to TESI. Although scar size reduction was evident in all scar segments, scar size reduction and ventricular functional responses preferentially occurred at the sites of TESI versus non-TESI sites. Furthermore, improvement was greatest when segmental left ventricular dysfunction was severe.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Res

DOI

EISSN

1524-4571

Publication Date

April 11, 2014

Volume

114

Issue

8

Start / End Page

1292 / 1301

Location

United States

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Treatment Outcome
  • Tomography, Spiral Computed
  • Stroke Volume
  • Myocardial Infarction
  • Muscle Development
  • Middle Aged
  • Mesenchymal Stem Cell Transplantation
  • Male
  • Injections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Suncion, V. Y., Ghersin, E., Fishman, J. E., Zambrano, J. P., Karantalis, V., Mandel, N., … Heldman, A. W. (2014). Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ Res, 114(8), 1292–1301. https://doi.org/10.1161/CIRCRESAHA.114.302854
Suncion, Viky Y., Eduard Ghersin, Joel E. Fishman, Juan Pablo Zambrano, Vasileios Karantalis, Nicole Mandel, Katarina H. Nelson, et al. “Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.Circ Res 114, no. 8 (April 11, 2014): 1292–1301. https://doi.org/10.1161/CIRCRESAHA.114.302854.
Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Karantalis V, Mandel N, Nelson KH, Gerstenblith G, DiFede Velazquez DL, Breton E, Sitammagari K, Schulman IH, Taldone SN, Williams AR, Sanina C, Johnston PV, Brinker J, Altman P, Mushtaq M, Trachtenberg B, Mendizabal AM, Tracy M, Da Silva J, McNiece IK, Lardo AC, George RT, Hare JM, Heldman AW. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ Res. 2014 Apr 11;114(8):1292–1301.

Published In

Circ Res

DOI

EISSN

1524-4571

Publication Date

April 11, 2014

Volume

114

Issue

8

Start / End Page

1292 / 1301

Location

United States

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Treatment Outcome
  • Tomography, Spiral Computed
  • Stroke Volume
  • Myocardial Infarction
  • Muscle Development
  • Middle Aged
  • Mesenchymal Stem Cell Transplantation
  • Male
  • Injections